

December 1, 2016



CytoDyn to Present at LD Micro Main Event on December 7

VANCOUVER, Washington, Dec. 01, 2016 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new monoclonal antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that Nader Pourhassan, Ph.D., President and CEO, will present at the LD Micro Main Event on December 7, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The conference is being held at the Luxe Sunset Hotel in Los Angeles.

A live webcast of the presentation will be available on the Company's website at www.cytodyn.com under the Investors section/IR Calendar or at <http://wsw.com/webcast/ldmicro11/cydy> and will be archived for 90 days. Web participants are encouraged to login to either website 15 minutes prior to the start of the webcast to register, download and install any necessary software.

About CytoDyn

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV and to pursue non-HIV indications where CCR5 and its ligand CCL5 may be involved. For more information on the Company, please visit www.cytodyn.com.

About PRO 140

PRO 140 belongs to a new class of HIV/AIDS therapeutics – viral-entry inhibitors – that are intended to protect healthy cells from viral infection. PRO 140 is a humanized IgG4 monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 blocks the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5. Importantly, PRO 140 does not appear to interfere with the normal function of CCR5 in mediating immune responses. PRO 140 does not have agonist activity toward CCR5 but does have antagonist activity to CCL5, which is a central mediator in inflammatory diseases. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects. PRO 140 has been designated a “fast track” product candidate by the FDA. The

PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.

Investors:

LHA

Jody Cain

Office: 310-691-7100

E-mail: jcain@lhai.com

Media:

Nader Pourhassan, Ph.D.

Office: 360-980-8524

E-mail: npourhassan@cytodyn.com



Source: CytoDyn Inc.